Results 51 to 60 of about 10,096 (205)

Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer

Frontiers in Oncology, 2015
The MYCN proto-oncogene is associated with poor outcome across a broad range of pediatric tumors. While amplification of MYCN drives subsets of high risk neuroblastoma and medulloblastoma, dysregulation of MYCN in medulloblastoma (in the absence of ...
Tene Aneka Cage, Yvan eChanthery, Yvan eChanthery, Louis eChesler, Matthew eGrimmer, Matthew eGrimmer, Zachary eKnight, Kevan eShokat, William A Weiss, William A Weiss, William A Weiss, William A Weiss, W. Clay Gustafson, W. Clay Gustafson   +13 more
doaj   +1 more source

MYCN amplification levels in primary retinoblastoma tumors analyzed by Multiple Ligation-dependent Probe Amplification

Ophthalmic Genetics, 2021
Background: Retinoblastoma (Rb) is a childhood tumor of the developing retina where predisposition is caused by RB1 pathogenic variants. MYCN amplification (MYCNA) has been implicated in around 2% of sporadic unilateral Rb tumors with no detectable RB1 variants.
Elizabeth A. Price, Roopal Patel, Irene Scheimberg, Esin Kotiloglu Karaa, Mandeep S. Sagoo, M. Ashwin Reddy, Zerrin Onadim   +6 more
openaire   +3 more sources

Detection of MYCN Gene Amplification in Neuroblastoma by Fluorescence In Situ Hybridization: A Pediatric Oncology Group Study

Neoplasia: An International Journal for Oncology Research, 2001
To assess the utility of fluorescence in situ hybridization (FISH) for analysis of MYCN gene amplification in neuroblastoma, we compared this assay with Southern blot analysis using tumor specimens collected from 232 patients with presenting ...
Prasad Mathew, Marcus B. Valentine, Laura C. Bowman, Susan T. Rowe, Michael B. Nash, Virginia A. Valentine, Susan L. Cohn, Robert P. Castleberry, Garrett M. Brodeur, A. Thomas Look   +9 more
doaj   +1 more source

Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma

Cell Reports, 2020
Summary: Loss of heterozygosity (LOH) at 1p36 occurs in multiple cancers, including neuroblastoma (NBL). MYCN amplification and 1p36 deletions tightly correlate with markers of tumor aggressiveness in NBL.
Jesus García-López, Kirby Wallace, Joel H. Otero, Rachelle Olsen, Yong-dong Wang, David Finkelstein, Brian L. Gudenas, Jerold E. Rehg, Paul Northcott, Andrew M. Davidoff, Kevin W. Freeman   +10 more
doaj   +1 more source

Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells

Scientific Reports, 2022
Neuroblastoma is a childhood tumour that is responsible for approximately 15% of all childhood cancer deaths. Neuroblastoma tumours with amplification of the oncogene MYCN are aggressive, however, another aggressive subgroup without MYCN amplification ...
Sanja Jurcevic, Simon Keane, Emmy Borgmästars, Zelmina Lubovac-Pilav, Katarina Ejeskär   +4 more
doaj   +1 more source

Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior [PDF]

Journal of Neuropathology & Experimental Neurology, 2019
Abstract Adult spinal cord ependymomas are typically low grade and have a relatively favorable clinical course following gross total resection. We report 4 cases of anaplastic spinal cord ependymoma with MYCN amplification, an exceptionally rare finding.
Swanson A. A., Raghunathan A., Jenkins R. B., Messing-Junger M., Pietsch T., Clarke M. J., Kaufmann T. J., Giannini C.   +7 more
openaire   +3 more sources

Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults

Case Reports in Oncological Medicine, 2013
MYCN is a well-known oncogene overexpressed in different human malignancies including neuroblastoma, rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms’ tumor, and small cell lung cancer.
Anna Koumarianou, Panagiota Oikonomopoulou, Margarita Baka, Dimitrios Vlachodimitropoulos, Stylianos Argentos, Theodoros Piperos, Maria-Ioanna Christodoulou, Kakoulis Theodoulou, Theodoros Mariolis-Sapsakos   +8 more
doaj   +1 more source

MYCN Gene Copy Number Status Detected by FISH Method and Its Correlation with Outcome and Clinicopathological Variables in Childhood Neuroblastoma [PDF]

Middle East Journal of Cancer
Background: Neuroblastoma is the most common extracranial solid tumor in children. MYCN gene amplification (MNA) is an independent prognostic factor for rapid tumor progression and poor prognosis, regardless of age and clinical stage.
Mahdi Shahriari, Akbar Safaei, Parvaneh Davoudi, Bozorgmehr Hedayati   +3 more
doaj   +1 more source

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

Nature Communications, 2022
Half of high-risk neuroblastoma patients have MYCN amplification. Here, the authors show that MYCN induces fatty acid uptake and synthesis to support neuroblastoma and inhibition of a fatty acid transporter impairs tumor progression in preclinical models.
Ling Tao, Mahmoud A. Mohammad, Giorgio Milazzo, Myrthala Moreno-Smith, Tajhal D. Patel, Barry Zorman, Andrew Badachhape, Blanca E. Hernandez, Amber B. Wolf, Zihua Zeng, Jennifer H. Foster, Sara Aloisi, Pavel Sumazin, Youli Zu, John Hicks, Ketan B. Ghaghada, Nagireddy Putluri, Giovanni Perini, Cristian Coarfa, Eveline Barbieri   +19 more
doaj   +1 more source

CD133 expression and amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma

Journal of International Medical Research, 2018
Objectives Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial.
Zhi-Yong Zhong, Bao-Jun Shi, Hui Zhou, Wen-Bo Wang   +3 more
doaj   +1 more source